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with high dose chemotherapy and stem cell rescue for CNS
tumors have disrupted sleep and thosewith high risk disease
appear to have poorer sleep quality in comparison to average
risk. Poorer sleep quality in high risk patients may be a result
of more extensive surgery, residual tumor and higher doses
of radiation. Lastly, nurses play a role in optimizing the sleep
environment for patients; attention needs to be focused on
sleep interventions for high risk patients undergoing stem
cell transplantation.
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Hear Our Voices: Patient’s Perspective of Financial Impact
of Allogeneic HCT
Mary Weise, Nandita Khera, Pierre Noel. Mayo Clinic Arizona,
Phoenix, Arizona
Topic Signiﬁcance & Study Purpose/Background/
Rationale: Medical science has made great improvement
in Allogeneic Hematopoietic Cell Transplantation (HCT) over
recent decades. Current treatment modalities offer many
recipients curative treatment or increased long-term survi-
vorship. Practice guidelines are working to identify and
improve patient care outcomes and long-term effects of HCT,
offering patients an opportunity to live with their disease
post-transplant. However, the reality is that, for many, sur-
viving HCT offers a mixed blessing. Many practitioners have
identiﬁed frustrations in post-transplant follow-up care
related to the ﬁnancial impact of HCT care. Patients report
devastating impacts upon quality of life (QOL), beyond the
medical concerns of GVHD or other chronic health problems
related to HCT. They report life stressors which may ulti-
mately affect their health and well-being. While much has
been done to offer improved survivorship and quality of care
with HCT, little seems to have been studied regarding the
QOL and ﬁnancial impact of HCT upon post-transplant
survivors.
Methods, Intervention, & Analysis: Data analysis included
qualitative analysis based on a questionnaire which was
mailed to 482 patients (268 respondents¼ 56%) who had
survived allogeneic HCT at the 3 study sites at Mayo Clinic
from 1/06 to 6/12. Questions in the survey were about health
insurance, prescription/medical costs, and employment
which allowed for subjective data on illness and the impact
that HCT has on one’s QOL, physical and emotional well-
being, personal ﬁnances, as well as resource allocation post-
HCT. A section in the questionnaire allowed for patient
comments. This study discusses their open-ended, candid
responses to the impact of transplant. It also allowed for any
thoughts in information that could have helped them better
prepare ﬁnancially for post-transplant care.
Findings & Interpretation: Our sample (n¼268 re-
spondents) reported issues with employment, insurance,
and disability. A majority conveyed an adverse ﬁnancial
impact (>54%) such as a reduction in household income
>50%, need to sell/mortgage home, withdraw money from
savings, and paying more than they could afford for their
medical care. 73% reported that being sick had hurt them
ﬁnancially, with 3% declaring bankruptcy.
Conclusions: A signiﬁcant proportion of post-HCT survivors
report an impact on their personal ﬁnances and QOL, despite
having health insurance coverage. Future research could help
identify at-risk patients, counsel resources, and support in-
terventions which could improve outcomes of HCT.
Discussion & Implications: As transplant practitioners, we
are trying to be advocates of cancer survivorship, yet
consideration of QOL and the ﬁnancial impact of transplantcare should be considered if we are to practice ethically.
Recommendations for correlating QOL studies in HCT, can
help to improve patient outcomes throughout the contin-
uum of care, while helping our patients in what can be life-
long coping with chronic survivorship. Open-ended patient
responses help give practioners a sense of the emotion and
depth of impact as they tell us how transplant affected their
lives. It is important to let patient’s know we are listening, so
that we can open paths for conversation and improve out-
comes.TRANSPLANT NURSING RESEARCH
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Comparing the safety and efﬁcacy of red blood cell
transfusion dose in hematopoietic stem cell transplant
patients: single versus double unit transfusions
Rhonda Evans, Aldijana Avdic, Anne Smith, Sharon Tucker.
University of Iowa Hospitals & Clinics, Iowa City, Iowa
Topic Signiﬁcance & Study Purpose/Background/
Rationale: Until recently, the national standard practice for
blood transfusions in bone marrow transplant patients was
two units of red blood cells (RBCs) per transfusion episode.
This practice was called into question due to safety concerns,
suggesting that one unit of RBCs per transfusion episodemay
be an equivalent or even safer and less costly practice
(assuming factors such as amount of bleeding and hemo-
globin level are equal). Following a thorough review of
existing blood management practices and review of the
literature, our academic medical center changed practice to
routinely transfuse one unit of RBCs per low hemoglobin (7-8
g/dL) episode if certain clinical criteria were met. Following
IRB approval, a retrospective medical record review began to
evaluate this practice change among two groups of hema-
tology-oncology patient populations (allogeneic and autol-
ogous bone marrow transplant). Patient records from these
two groups of patients are being evaluated before and after
the practice change (one vs two units of RBCs/transfusion)
looking at average units of blood products transfused per
patient, impact on length of stay, and estimate of nursing
time costs. The project is expected to generate new knowl-
edge regarding safe blood management practices in hema-
tology oncology patients.
Methods, Intervention, & Analysis: The project is using the
hematology oncology inpatient unit log of admissions and
discharges to identify adult allogeneic and autologous bone
marrow transplant patients who received a blood trans-
fusion for a hemoglobin of 7-8g/dl and hematocrit above
21%; and were not actively bleeding, septic, experiencing a
major infection, or pregnant. Patient data are being obtained
from the University HealthSystem Consortium (UHC) data-
base. 400 cases are being enrolled, 200 from pre-practice
change (7-1-2009 to 6-30-2011) and 200 from post-practice
change (9-1-2011 to 8-31-2013). A two-month gap was
purposefully included between the two time periods to allow
for full transition to the new practice standard of one unit of
RBCs/transfusions. Data thus far suggests a reduction in red
blood cell utilization at an average of 1.3 units per hospital
discharge. Based on these utilization trends, we are esti-
mating a cost savings of at least $1300 per month just in
purchase cost ($200 per RBC unit X 1.3 units per discharge X
an average of 5 patients/month). Additionally, we are esti-
mating a savings in nursing hours of approximately 13 hours
per month (2 hours per RBC transfusion X 1.3 units per
discharge X an average of 5 patients/month).
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indicate promise for the standard practice of transfusing one
unit of RBCs per low hemoglobin episode for allogeneic bone
marrow transplant and autologous bone marrow transplant
patients. After data collection is complete, formal statistics
will be completed to compare the mean number of RBC units
between the practice of routinely transfusing 1 RBC unit and
the practice of routinely transfusing 2 RBC units, as well as
comparing length of stay and costs. Early conclusions suggest
the goal of improving the safety of blood transfusions and
preserving a precious resource might be achieved with this
important practice change for two groups of oncology pa-
tients. These results will inform other practice settings to
improve their use of blood management products for
oncology patients and promote patient safety and cost-
effective practices. Use of the UHC database as a meaningful
resource for practice improvement projects and research
studies will be highlighted. Continued evaluation and
ongoing improvement of blood management practices at the
project site will be discussed with suggestions for other
settings and practices.
Discussion & Implications: This will help improve the
safety of blood transfusions. It could guide future studies
with baseline information from this transfusion practice
change. Other oncology areas could adopt a similar practice
change, educate patients and clinicians on safe transfusion
practices.122
Away with the Alcohol: The Impact on Clostridium
Difﬁcile Infection (CDI) Rate on a Complex Bone Marrow
Transplant Unit
Laura Flesch, Melissa Hayward, Kathy Demmel,
Ra’Shawn Brown, Michael Cloughessy. Cincinnati Children’s
Hospital Medical Center, Cincinnati, Ohio
Topic Signiﬁcance & Study Purpose/Background/
Rationale: This Bone Marrow Transplant Unit (BMT) is a 24
bed critical care environment that cares for a highly complex
patient population with underlying oncologic, immunologic,
marrow failure, and metabolic disorders. Hand hygiene is
stressed and alcohol gel products are located inside and
outside patient rooms. Infection Control (IC) conducts daily
surveys for patient infections and reports them to BMT staff.
During 2009, an increase in Clostridium Difﬁcile Infection
(CDI) cases was detected on the BMT unit.
Methods, Intervention, & Analysis: Due to the frequency of
CDI, isolation and environmental cleaning practices were
evaluated. Bleachwas implemented for discharge cleaning and
hand washing with soap and water on patient room exit was
reinforced with education and signage, to both staff and
caregivers. BMT staff and IC implemented initiatives to de-
clutter the unit and facilitate environmental cleaning. After
these initiatives, the number of CDI remained high. After re-
view, in September of 2010, alcohol gelswere removed from all
patient rooms and a “gel in, wash out” initiative was adopted.
Findings & Interpretation: After alcohol gel was removed
from patient rooms, the number of CDI cases has fallen and
the days between CDI have increased. In the midst of other
interventions, it appears the greatest impact for the decrease
was related to the simple intervention of removing alcohol
gel from inside patient rooms, and instituting hand washing
with soap and water before exiting a patient room. Prior to
the alcohol gel removal, the CDI rate was 1.68 infections per
1000 patient days. The intervention decreased the rate to
0.35 infections per 1000 patient days, a signiﬁcant 79% rate
reduction.Discussion & Implications: Hand washing when exiting
patient rooms enhances patient safety by removing Clos-
tridium Difﬁcile spores and other pathogens that may not be
killed by alcohol gel products.123
Human Herpes Virus-6 Viremia is associated with poor
clinical outcomes in Children following Allogeneic
Hematopoietic Cell Transplantation (AlloHCT)- Statistical
Noise or a Real problem?
Leah Violago, Evelyn Rustia, Zhezhen Jin, Monica Bhatia,
Andrew Kung. Department of Nursing, New York-Presbyterian
Morgan Stanley Children’s Hospital, NewYork, New York
Topic Signiﬁcance & Study Purpose/Background/
Rationale: Human Herpes Virus 6 (HHV-6) is an evolving
pathogen in the ﬁeld of AlloHCT. The impact of HHV-6
viremia on AlloHCT outcomes in children has not been well
described. At our center, one patient died fromHHV-6 and/or
its treatment; another asymptomatic patient had a very high
HHV-6 viral load (>1 million copies/ml) that was refractory
to treatment with Ganciclovir, Foscarnet and Cidofovir. These
two cases prompted us to create a standard operating pro-
cedure for HHV6 monitoring in an effort analyze the clinical
impact of HHV-6 viremia following AlloHCT.
Methods, Intervention, & Analysis: We monitored weekly
HHV-6 PCR starting pre-AlloHCT and up to Day +180 post-
transplant from 2008-2012 on 100 children (median age, 8
years; range 0.25-22 years; 35 F/65 M) undergoing AlloHCT
for both malignant (n¼53) and non-malignant (n¼47) dis-
eases. Conditioning regimens consisted of either myeloa-
blative (n¼43, 43%), reduced toxicity (n¼34, 34%) or reduced
intensity (n¼23, 23%) regimens with 47% of total patients
receiving alemtuzumab and 30% of total patients receiving
rabbit anti-thymocyte globulin. Donor sources included
matched family donor (n¼42, 42%), matched unrelated
donor (n¼28, 28%) and unrelated cord blood (n¼20, 20%).
Findings & Interpretation: The incidence of pre-AlloHCT
HHV-6 viremia was 3% (n¼3). Following AlloHCT, 18 patients
developed HHV-6 viremia and 10 patients had recurrence of
viremia. The incidence of peri-AlloHCT (day 0- day+14), early
(day +15-day+98) and late HHV-6 viremia (>day +98) was
5%, 14% and 9%, respectively. The average time to clear
viremia was 6 weeks (range 1-23 weeks). The median time
to platelet engraftment in patients with HHV-6 viremia
was delayed in relation to unaffected patients (p¼0.004).
Furthermore, the incidence of platelet engraftment by day
+180 was lower in patients with viremia than in unaffected
counterparts (p¼0.038). Overall, HHV-6 viremia was associ-
ated with higher transplant- related mortality [TRM] (0.003)
[Table] though we did not observe any case of encephalop-
athy or deaths directly related to the HHV-6 itself.
Discussion & Implications: With this study, we demon-
strate that HHV-6 is prevalent in children undergoing
AlloHCT and that HHV-6 viremia is associated with signiﬁ-
cant platelet engraftment delay and transplant related mor-
tality. Further clinical sequelae of HHV-6 viremia remain
difﬁcult to ascertain. Each PCR test costs $120 resulting in
approximately $250,000-300,000 of hospital cost over the
four-year study period. . Due to lack of clear understanding of
clinical consequences, we no longer routinely perform PCR
monitoring of HHV-6. To elucidate the role of HHV-6, uni-
variate and multivariate analysis will be conducted to study
various risk factors that may contribute to delayed platelet
engraftment and TRM post-AlloHCT in an effort to identify
who might beneﬁt from routine HHV-6 PCR monitoring in
the future.
